Gneebio Enrofloxacin is an efficient, broad-spectrum antibiotic that has been trusted in the U.S. cattle industry for 25 years. Once injected into cattle, enrofloxacin is metabolized into enrofloxacin and ciprofloxacin. These molecules deliver different modes of action for optimal efficacy. Therefore it delivers prompt, combined strengths against the primary pathogens that cause bovine respiratory disease (BRD).
Gneebio Enrofloxacin works quickly at the infection site with enrofloxacin reaching peak plasma concentration in less than two hours. It remains active because ciprofloxacin has a maximum residence time of 13.7 hours.
A single injection of enrofloxacin has a relatively brief period of effect. After a single subcutaneous injection of 12.5 mg/kg, the combined, unbound concentrations of enrofloxacin and ciprofloxacin are below the minimal inhibitory count (MIC) for 90% of Mannheimia haemolytica isolates in plasma and tissue fluids by 48 hours. Do not exceed a 20 mL dose per injection site. Subcutaneous injection in cattle can cause a transient local tissue reaction and may result in trim loss of edible tissue at slaughter.
Designed to deliver broad-spectrum efficacy
Enrofloxacin is a broad-spectrum antibiotic with a low minimal inhibitory concentration on the primary agents of bovine respiratory disease.